vcn-01
Generic: zabilugene almadenorepvec·Code: VCN-01
vcn-01: developed by 1 company · 1 clinical trial tracked · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Theriva Biologics, Inc. (TOVX) | Phase 2 |
Clinical Trials (1)
A Phase IIb, Open-label, Randomized Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer
FDA Decisions
FDA_MeetingFDA agreed with the proposed Phase 3 trial design, dosing, endpoints, and adaptive design for VCN-01 in metastatic PDAC.(TOVX)
Frequently asked questions
Who is developing vcn-01?
vcn-01 is being developed by Theriva Biologics, Inc..
How many clinical trials involve vcn-01?
BioSniper tracks 1 clinical trial involving vcn-01.
What is vcn-01's latest FDA decision?
The most recent tracked FDA decision for vcn-01 is FDA_Meeting for FDA agreed with the proposed Phase 3 trial design, dosing, endpoints, and adaptive design for VCN-01 in metastatic PDAC..
Get deeper analysis on vcn-01
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis